Kalkofen Donald A. 4
4 · Protagonist Therapeutics, Inc · Filed Feb 17, 2022
Insider Transaction Report
Form 4
Kalkofen Donald A.
Chief Financial Officer
Transactions
- Award
Common Stock
2022-02-15+7,500→ 18,521 total - Award
Stock Option (right to buy)
2022-02-15+45,000→ 45,000 totalExercise: $28.73Exp: 2032-02-14→ Common Stock (45,000 underlying)
Footnotes (3)
- [F1]Represents grant of restricted stock units payable solely in common stock that will vest in three annual installments on February 15, 2023, 2024 and 2025.
- [F2]Includes an aggregate of 635 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on March 9, 2021.
- [F3]The stock option vests in 48 equal monthly installments following the date of grant.